Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial.

作者：Yongxiang Xia, Xiaofeng Wu, Aihua Yao, Xiaofeng Qian, Xinzheng Dai, Feng Zhang, Xiuli Wang, Chuanyong Zhang, Liyong Pu, Donghua Li, Wang Ping, Feng Cheng, Jie Zhao, Hui Zhang, Weiwei Tang, Yongxiang Zhan, Jinxue Zhou, Bin Zhang, Xiangcheng Li, Xuehao Wang · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.e16279 · 被引用次数：1 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Pancreatic and Hepatic Oncology Research、Liver Disease Diagnosis and Treatment

e16279 Background: The high recurrence rate following resection presents a significant challenge to the survival of patients with resectable hepatocellular carcinoma (HCC). Therefore, it is imperative to develop novel and effective therapeutic interventions to reduce recurrence and improve the prognosis of patients with resectable HCC. This study aims to evaluate the efficacy and safety of camrelizumab combined with rivoceranib and TACE as a perioperative treatment regimen in patients with HCC. Methods: In this multicenter, randomized clinical trial, eligible HCC patients (CNLC stages Ib-IIIa) were randomly assigned in a 1:1 ratio to either the treatment or control group. Patients in the treatment group received one cycle of TACE, followed by 2 cycles of camrelizumab (200 mg Q2W) combined with rivoceranib (250 mg QD), and subsequently proceeded to surgery. At least six cycles of sequential therapy of camrelizumab (200 mg Q3W) plus rivoceranib (250 mg QD) was performed postoperatively.Patients in the control group received surgical resection followed by at least six cycles of treatment with camrelizumab (200 mg Q3W) plus rivoceranib (250 mg QD). The primary endpoint was 2-year event-free survival rate. Secondary endpoints were major pathological response (MPR) (defined as ≤10% viable tumor cells in the tumor bed), pathologic complete response rate (pCR), disease-free survival (DFS), overall survival (OS), and safety. Results: From March 2023 to November 2024, 60 patients with ...